In 1996, the US Food and Drug Administration (USFDA) approved intravenous tissue plasminogen activator (IV tPA) for the treatment of acute ischemic stroke within 3 h of onset of symptoms (The National Institute of neurological Disorders and Stroke rt-PA Stroke Study Group, 1995). This evidence concerns the gene PLAT and stroke disorder.